Exhibit 99.1

FOR IMMEDIATE RELEASE

CONTACT:
Robert Low                                      Bob Bannon
Vice President Finance & Acting CFO             Sr. Director, Investor Relations
rlow@advancispharm.com                          rbannon@advancispharm.com
301-944-6690                                    301-944-6710

                        ADVANCIS PHARMACEUTICAL ANNOUNCES
                        RESIGNATION OF STEVEN SHALLCROSS

            ROBERT LOW, FORMER ADVANCIS CONTROLLER, NAMED ACTING CFO

GERMANTOWN, Md. - October 24, 2005 - Advancis Pharmaceutical Corporation
(NASDAQ:AVNC), a pharmaceutical company focused on developing and
commercializing novel anti-infective products, today announced the resignation
of Steven A. Shallcross, effective November 4, 2005. Robert C. Low, who has
served as corporate controller since joining Advancis in August 2003, has been
promoted to Vice President Finance and Acting CFO, effective immediately.

"Steve has been a driving force in assembling the Advancis finance team,
completing our IPO, and building a sound infrastructure for our financial
reporting and controls. I would like to thank him for his hard work and valuable
contributions to the Company" said Edward M. Rudnic, Ph.D., chairman, president
and CEO of Advancis. "Bob Low has been a critical part of our management team
since joining Advancis. His contributions in leading our financial reporting
processes and regulatory compliance initiatives position him extremely well to
assume the additional responsibilities of acting chief financial officer."

Mr. Low joined Advancis in August 2003 as corporate controller and has been
responsible for the Company's accounting, tax, financial reporting, and internal
controls since that time. Prior to joining Advancis, he was senior vice
president and corporate controller for American Medical Laboratories, Inc. prior
to its acquisition by Quest Diagnostics, Inc. Mr. Low has an extensive
background in public accounting, auditing, and in senior accounting positions
with publicly-traded companies. He is also a Certified Public Accountant.

Mr. Shallcross' departure was based upon mutual agreement with the Company. He
will stay on with the Company through November 4, 2005 to assist in transitional
activities.



ABOUT ADVANCIS PHARMACEUTICAL:
Advancis Pharmaceutical Corporation (NASDAQ: AVNC) is a pharmaceutical company
focused on the development and commercialization of pulsatile drug products that
fulfill substantial unmet medical needs in the treatment of infectious disease.
The Company is developing a broad portfolio of anti-infective drugs based on its
novel biological finding that bacteria exposed to antibiotics in frontloaded
staccato bursts, or "pulses," are killed more efficiently and effectively than
those under standard treatment regimens. Based on this finding, Advancis has
developed a proprietary, once-a-day pulsatile delivery technology called PULSYS.
By examining the resistance patterns of bacteria and applying its delivery
technologies, Advancis has the potential to redefine infectious disease therapy
and significantly improve drug efficacy, shorten length of therapy, and reduce
drug resistance versus currently available antibacterial products. For more on
Advancis, please visit www.advancispharm.com.

This announcement contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These statements are based on
Advancis' current expectations and assumptions. These statements are not
guarantees of future performance and are subject to a number of risks and
uncertainties that would cause actual results to differ materially from those
anticipated. The words, "believe," "expect," "intend," "anticipate," and
variations of such words, and similar expressions identify forward-looking
statements, but their absence does not mean that the statement is not
forward-looking. Statements in this announcement that are forward-looking
include, but are not limited to, statements about the Company's future
development plans, clinical trials, and financial results. The actual results
realized by Advancis could differ materially from these forward-looking
statements, depending in particular upon the risks and uncertainties described
in the Company's filings with the Securities and Exchange Commission. These
include, without limitation, risks and uncertainties relating to the Company's
financial results and the ability of the Company to (1) reach profitability, (2)
prove that the preliminary findings for its product candidates are valid, (3)
receive required regulatory approvals, (4) successfully conduct clinical trials
in a timely manner, (5) establish its competitive position for its products, (6)
develop and commercialize products that are superior to existing or newly
developed competitor products, (7) develop products without any defects, (8)
have sufficient capital resources to fund its operations, (9) protect its
intellectual property rights and patents, (10) implement its sales and marketing
strategy, (11) successfully attract and retain collaborative partners, (12)
implement its workforce reduction, and (13) retain its senior management and
other personnel. Existing and prospective investors are cautioned not to place
undue reliance on these forward-looking statements, which speak only as of
today's date. Advancis undertakes no obligation to update or revise the
information in this announcement, whether as a result of new information, future
events or circumstances or otherwise.

                                       ###